Form 6-K GLAXOSMITHKLINE PLC For: Nov 30
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 30 November
2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc
(the 'Company')
Transaction
notification
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|||
a)
|
Name
|
Mr S
Dingemans
|
||
b)
|
Position/status
|
Chief
Financial Officer
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of the transaction
|
The
grant of options over Ordinary Shares pursuant to the Company's
ShareSave Plan 2016.
|
||
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.95
|
208
|
|||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a
(single transaction)
|
||
e)
|
Date of
the transaction
|
2016-11-30
|
||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|||
a)
|
Name
|
Mr S A
Hussain
|
||
b)
|
Position/status
|
President,
Global Pharmaceuticals
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of the transaction
|
The
grant of options over Ordinary Shares pursuant to the Company's
ShareSave Plan 2016.
|
||
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.95
|
694
|
|||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a
(single transaction)
|
||
e)
|
Date of
the transaction
|
2016-11-30
|
||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
|||
a)
|
Name
|
Mr P C
Thomson
|
||
b)
|
Position/status
|
SVP,
Communications & Government Affairs
|
||
c)
|
Initial
notification/
amendment
|
Initial
notification
|
||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|||
a)
|
Name
|
GlaxoSmithKline
plc
|
||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
||
b)
|
Nature
of the transaction
|
The
grant of options over Ordinary Shares pursuant to the Company's
ShareSave Plan 2016.
|
||
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£12.95
|
277
|
|||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a
(single transaction)
|
||
e)
|
Date of
the transaction
|
2016-11-30
|
||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: November
30, 2016
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WuXi Biologics Reports Solid 2023 Annual Results
- NORTH COAST BREWING CO. AND WESTWARD WHISKEY FORGE UNIQUE PARTNERSHIP
- Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!